Connect with us

CAB-LA

  •  Some experts world leaders and stars around the world have called for the dramatic reduction in price of the ground breaking new HIV medicines to ensure global accessibility to all who need them The News Agency of Nigeria reports that some of the advocates included Nobel laureates Fran oise Barr Sinoussi and Joseph Stiglitz former President of Malawi Dr Joyce Banda and former New Zealand Prime Minister Helen Clark Others are artistes Olly Alexander singer and actor Stephen Fry actor writer and presenter Adam Lambert singer and songwriter David Oyelowo actor producer director and Arnaud Valois actor Also business leaders Mo Ibrahim and Paul Polman are amongst those who have joined the call in an open letter The letter was published in the run up to the International AIDS Conference which opened in Montreal on July 29 AIDS pandemic continues to take a life every minute and new HIV infections are rising in too many communities The breakthrough long acting medicine only has to be taken every few months and is proving to be one of the most effective methods to prevent HIV transmission In addition to the prevention tool available now long acting antiretrovirals could one day be part of revolutionizing treatment to prevent deaths But these medicines are currently only available in high income countries at a price of tens of thousands of dollars far out of reach for people and governments in low and middle income countries People in these countries need them most they said in the letter The advocates said that these long acting HIV medicines could enable millions of adolescent girls and young women in sub Saharan Africa to protect themselves from acquiring HIV According to them they can enable people from marginalised communities including gay men transgender people and sex workers to receive a discreet injection every few months to protect themselves The letter called on ViiV one of the world s largest HIV pharmaceutical companies to share their technology and know how to boost production and set their price at a point where all countries could afford to buy these medicines In particular it called on ViiV to tackle the barriers to access by taking some steps Announce a lower price for the long acting injectable ARV for prevention CAB LA as close as possible to that of other HIV prevention medicines PrEP The current best PrEP option is approximately 60 per person per year Make the price public and transparent and include the cost of the accompanying syringe Quickly finalise licences to produce generic versions of this long acting ARV through the Medicines Patent Pool Licence across the world s low and middle income countries on a non exclusive basis with a broad geographic scope for both treatment and prevention Share know how and technology Enable producers in Africa Asia Latin America Eastern and Central Europe and beyond to seek transfer and begin producing Commit to making enough to meet demand until generic producers come online Lilian Mworeko Regional Coordinator of the International Community of Women Living with HIV Eastern Africa ICWEA said While many in the global North are getting access to long acting HIV prevention tools and medicines Africans are overwhelmingly denied the opportunity It is worse for groups who continue to be left behind like adolescent girls and young women As long as the price is unaffordably high for our governments and for funders to purchase we will continue to be locked out from being able to access them They are vital to preventing new HIV infections and they could become transformational in treatment Our message is simple all of our lives matter she said As the global HIV response has come under strain from the COVID 19 crisis and the Ukraine war ensuring rapid affordable and equitable access to these medicines has become even more urgent The signatories to the letter stressed that they could and must be made available to everyone regardless of the passport they hold or the money in their pocket They said that the new medicines present a remarkable opportunity to avoid the scientific and policy mistakes that defined the early years of AIDS whereby after the first antiretroviral HIV drugs received approval prohibitive costs meant they were out of reach in the global South They said that millions died and that the failings were not due to scientific or technical limitations but as the result of conscious choices about how medical innovation and access to health tools were organised and financed It is within ViiV s power to ensure that millions more people around the world are able to benefit from the incredible technical advances that have gone into this new medicine If countries know that it is available at an affordable price they will be able to prioritise the purchase of it from their health budgets and to make it available to all who need it said Deborah Gold CEO of the National Aids Trust Also Dr Ayoade Alakija Co Chair of the Africa Union Africa Vaccine Delivery Alliance for COVID 19 remarked There is a choice about how new medicines are launched into the global market in terms of whether they are available to everyone everywhere The limitations are less to do with scientific or technical challenges and much more to do with how medical innovation and access to health countermeasures are currently organised and financed to favour the rich and reinforce inequity The International AIDS Conference is taking place in Montreal from July 29 to Aug 2 2022 It offers an historic opportunity for ViiV to stand with world leaders civil society and people living with and at risk of HIV from around the world and pledge actions that will save lives and accelerate efforts to end AIDS as a public health threat by 2030 The World Health Organisation will release new guidelines on CAB LA the new medicines at the conference Winnie Byanyima Executive Director of UNAIDS said The stakes are high 40 million people around the world are living with HIV today and around 1 5 million people were newly infected in 2020 alone This is an issue of inequality Will these new medicines help us break down the inequalities driving the AIDS pandemic affordable and available for those who need them most Or will they stay out of reach The pharmaceutical industry has the opportunity to make medicines affordable and accessible to people in all countries including so called middle income countries through sharing technologies and setting an affordable price today until those generics come online NewsSourceCredit NAN
    Stakeholders call for accessibility of ground-breaking new HIV medicines
     Some experts world leaders and stars around the world have called for the dramatic reduction in price of the ground breaking new HIV medicines to ensure global accessibility to all who need them The News Agency of Nigeria reports that some of the advocates included Nobel laureates Fran oise Barr Sinoussi and Joseph Stiglitz former President of Malawi Dr Joyce Banda and former New Zealand Prime Minister Helen Clark Others are artistes Olly Alexander singer and actor Stephen Fry actor writer and presenter Adam Lambert singer and songwriter David Oyelowo actor producer director and Arnaud Valois actor Also business leaders Mo Ibrahim and Paul Polman are amongst those who have joined the call in an open letter The letter was published in the run up to the International AIDS Conference which opened in Montreal on July 29 AIDS pandemic continues to take a life every minute and new HIV infections are rising in too many communities The breakthrough long acting medicine only has to be taken every few months and is proving to be one of the most effective methods to prevent HIV transmission In addition to the prevention tool available now long acting antiretrovirals could one day be part of revolutionizing treatment to prevent deaths But these medicines are currently only available in high income countries at a price of tens of thousands of dollars far out of reach for people and governments in low and middle income countries People in these countries need them most they said in the letter The advocates said that these long acting HIV medicines could enable millions of adolescent girls and young women in sub Saharan Africa to protect themselves from acquiring HIV According to them they can enable people from marginalised communities including gay men transgender people and sex workers to receive a discreet injection every few months to protect themselves The letter called on ViiV one of the world s largest HIV pharmaceutical companies to share their technology and know how to boost production and set their price at a point where all countries could afford to buy these medicines In particular it called on ViiV to tackle the barriers to access by taking some steps Announce a lower price for the long acting injectable ARV for prevention CAB LA as close as possible to that of other HIV prevention medicines PrEP The current best PrEP option is approximately 60 per person per year Make the price public and transparent and include the cost of the accompanying syringe Quickly finalise licences to produce generic versions of this long acting ARV through the Medicines Patent Pool Licence across the world s low and middle income countries on a non exclusive basis with a broad geographic scope for both treatment and prevention Share know how and technology Enable producers in Africa Asia Latin America Eastern and Central Europe and beyond to seek transfer and begin producing Commit to making enough to meet demand until generic producers come online Lilian Mworeko Regional Coordinator of the International Community of Women Living with HIV Eastern Africa ICWEA said While many in the global North are getting access to long acting HIV prevention tools and medicines Africans are overwhelmingly denied the opportunity It is worse for groups who continue to be left behind like adolescent girls and young women As long as the price is unaffordably high for our governments and for funders to purchase we will continue to be locked out from being able to access them They are vital to preventing new HIV infections and they could become transformational in treatment Our message is simple all of our lives matter she said As the global HIV response has come under strain from the COVID 19 crisis and the Ukraine war ensuring rapid affordable and equitable access to these medicines has become even more urgent The signatories to the letter stressed that they could and must be made available to everyone regardless of the passport they hold or the money in their pocket They said that the new medicines present a remarkable opportunity to avoid the scientific and policy mistakes that defined the early years of AIDS whereby after the first antiretroviral HIV drugs received approval prohibitive costs meant they were out of reach in the global South They said that millions died and that the failings were not due to scientific or technical limitations but as the result of conscious choices about how medical innovation and access to health tools were organised and financed It is within ViiV s power to ensure that millions more people around the world are able to benefit from the incredible technical advances that have gone into this new medicine If countries know that it is available at an affordable price they will be able to prioritise the purchase of it from their health budgets and to make it available to all who need it said Deborah Gold CEO of the National Aids Trust Also Dr Ayoade Alakija Co Chair of the Africa Union Africa Vaccine Delivery Alliance for COVID 19 remarked There is a choice about how new medicines are launched into the global market in terms of whether they are available to everyone everywhere The limitations are less to do with scientific or technical challenges and much more to do with how medical innovation and access to health countermeasures are currently organised and financed to favour the rich and reinforce inequity The International AIDS Conference is taking place in Montreal from July 29 to Aug 2 2022 It offers an historic opportunity for ViiV to stand with world leaders civil society and people living with and at risk of HIV from around the world and pledge actions that will save lives and accelerate efforts to end AIDS as a public health threat by 2030 The World Health Organisation will release new guidelines on CAB LA the new medicines at the conference Winnie Byanyima Executive Director of UNAIDS said The stakes are high 40 million people around the world are living with HIV today and around 1 5 million people were newly infected in 2020 alone This is an issue of inequality Will these new medicines help us break down the inequalities driving the AIDS pandemic affordable and available for those who need them most Or will they stay out of reach The pharmaceutical industry has the opportunity to make medicines affordable and accessible to people in all countries including so called middle income countries through sharing technologies and setting an affordable price today until those generics come online NewsSourceCredit NAN
    Stakeholders call for accessibility of ground-breaking new HIV medicines
    General news2 months ago

    Stakeholders call for accessibility of ground-breaking new HIV medicines

    Some experts, world leaders, and stars around the world have called  for the dramatic reduction in price of the ground-breaking new HIV medicines, to ensure global accessibility to all who need them.The News Agency of Nigeria reports that some of the advocates included Nobel laureates Françoise Barré-Sinoussi and Joseph Stiglitz, former President of Malawi, Dr Joyce Banda and former New Zealand Prime Minister Helen Clark.Others are artistes Olly Alexander (singer and actor), Stephen Fry (actor, writer, and presenter), Adam Lambert (singer and songwriter), David Oyelowo (actor, producer, director) and Arnaud Valois (actor).Also, business leaders Mo Ibrahim and Paul Polman are amongst those who have joined the call in an open letter.The letter was published in the run up to the International AIDS Conference, which opened in Montreal on July 29. “ AIDS pandemic continues to take a life every minute, and new HIV infections are rising in too many communities.“The breakthrough long-acting medicine only has to be taken every few months and is proving to be one of the most effective methods to prevent HIV transmission.“In addition to the prevention tool available now, long-acting antiretrovirals could one day be part of revolutionizing treatment to prevent deaths.“But these medicines are currently only available in high-income countries at a price of tens of thousands of dollars – far out of reach for people and governments in low- and middle-income countries.“People in these countries need them most,’’ they said in the letter.The advocates said that these long-acting HIV medicines could enable millions of adolescent girls and young women in sub-Saharan Africa to protect themselves from acquiring HIV.According to them, they can enable people from marginalised communities including gay men, transgender people, and sex workers, to receive a discreet injection every few months to protect themselves.The letter called on ViiV, one of the world’s largest HIV pharmaceutical companies, to share their technology and know-how to boost production and set their price at a point where all countries could afford to buy these medicines.In particular, it called on ViiV to tackle the barriers to access by taking some steps.“Announce a lower price for the long-acting injectable ARV for prevention, CAB-LA, as close as possible to that of other HIV prevention medicines (PrEP).“The current best PrEP option is approximately $60 per person per year.Make the price public and transparent, and include the cost of the accompanying syringe.“Quickly finalise licences to produce generic versions of this long-acting ARV through the Medicines Patent Pool. “Licence across the world’s low- and middle-income countries on a non-exclusive basis, with a broad geographic scope for both treatment and prevention.“Share know-how and technology.Enable producers in Africa, Asia, Latin America, Eastern and Central Europe and beyond to seek transfer and begin producing.“Commit to making enough to meet demand until generic producers come online.’’ Lilian Mworeko, Regional Coordinator of the International Community of Women Living with HIV Eastern Africa (ICWEA), said: “While many in the global North are getting access to long-acting HIV prevention tools and medicines, Africans are overwhelmingly denied the opportunity.“It is worse for groups who continue to be left behind like adolescent girls and young women.“ As long as the price is unaffordably high for our governments and for funders to purchase, we will continue to be locked out from being able to access them.“They are vital to preventing new HIV infections and they could become transformational in treatment.“Our message is simple: all of our lives matter,’’ she said.As the global HIV response has come under strain from the COVID-19 crisis and the Ukraine war, ensuring rapid, affordable and equitable access to these medicines has become even more urgent.The signatories to the letter stressed that they could and must be made available to everyone, regardless of the passport they hold or the money in their pocket.They said that the new medicines present a remarkable opportunity to avoid the scientific and policy mistakes that defined the early years of AIDS whereby after the first antiretroviral HIV drugs received approval, prohibitive costs meant they were out of reach in the global South.They said that millions died and that the failings were not due to scientific or technical limitations but as  the result of conscious choices about how medical innovation and access to health tools were organised and financed.“It is within ViiV’s power to ensure that millions more people around the world are able to benefit from the incredible technical advances that have gone into this new medicine.“If countries know that it is available at an affordable price, they will be able to prioritise the purchase of it from their health budgets and to make it available to all who need it,’’ said Deborah Gold, CEO of the National Aids Trust.Also,  Dr Ayoade Alakija, Co-Chair of the Africa Union Africa Vaccine Delivery Alliance for COVID-19 , remarked.“There is a choice about how new medicines are launched into the global market in terms of whether they are available to everyone, everywhere.“The limitations are less to do with scientific or technical challenges and much more to do with how medical innovation and access to health countermeasures are currently organised and financed to favour the rich and reinforce inequity.’’ The International AIDS Conference, is taking place in Montreal from  July 29 to Aug. 2, 2022. It  offers an historic opportunity for ViiV to stand with world leaders, civil society and people living with and at risk of HIV from around the world and pledge actions that will save lives and accelerate efforts to end AIDS as a public health threat by 2030. The World Health Organisation will release new guidelines on CAB-LA – the new medicines – at the conference.Winnie Byanyima, Executive Director of UNAIDS, said: “The stakes are high.40 million people around the world are living with HIV today, and around 1.5 million people were newly infected in 2020 alone.“This is an issue of inequality.“Will these new medicines help us break down the inequalities driving the AIDS pandemic – affordable and available for those who need them most?Or will they stay out of reach?“The pharmaceutical industry has the opportunity to make medicines affordable and accessible to people in all countries, including so-called middle-income countries – through sharing technologies and setting an affordable price today until those generics come online.”NewsSourceCredit: NAN

  •  An agreement has been reached to allow the distribution of a low cost generic version of a long term preventive HIV treatment in low income countries where most of the world s infections occur Unitaid and the Medicines Patent Pool announced Thursday The deal will see ViiV Healthcare a subsidiary of UK pharmaceutical giant GSK allow select manufacturers to produce generic versions of Cabotegravir LA its long acting pre exposure prophylaxis PrEP treatment for HIV The deal will provide access to the injectable version of cabotegravir which has been shown to provide two months of protection against infection in 90 countries where more than 70 percent of all new HIV infections occurred in 2020 Unitaid said Access to an effective long acting HIV prevention option could make a significant contribution to the goal of ending HIV transmission and the epidemic by 2030 Unitaid spokesman Herve Verhoosel said Efforts to increase access to Cabotegravir LA for PrEP will have a particular impact for groups experiencing particularly high rates of infection such as men who have sex with men and sex workers he added Long acting cabotegravir injections have only recently become available and have been shown to be much more effective than an oral version that must be taken daily But cost the price of a year s worth of treatment was 22 000 in the United States earlier this year was an obstacle to widespread implementation in all but high income countries Top global priority The World Health Organization released new guidelines on cabotegravir on Thursday calling on countries to work to make the drug quickly available to those who need it We hope that these new guidelines will help accelerate countries efforts to begin planning for and offering CAB LA alongside other HIV prevention options said Meg Doherty director of global HIV hepatitis and sexually transmitted infections programs of the WHO in a statement The news comes a day after a new report presented at the International AIDS Conference in Montreal Canada which found that the global fight against HIV has stalled due to reduced resources due to Covid 19 and other crises Last year there were around 1 5 million new infections more than a million above global goals to fight the virus Long acting PrEP could play an important role in ending the HIV pandemic but right now very few people can get it said Adeeba Kamarulzaman president of the International AIDS Society which is organizing the conference Expanding affordable access to this game changing prevention tool must be a global priority he said in a statement Unitaid is a global health initiative that works to ensure equitable access to medical innovations in low and middle income countries The Medicines Patent Fund founded by Unitaid and supported by the UN works to obtain licenses for medicines needed for generic distribution in low and middle income countries
    They reach an agreement for a generic drug to prevent HIV infection
     An agreement has been reached to allow the distribution of a low cost generic version of a long term preventive HIV treatment in low income countries where most of the world s infections occur Unitaid and the Medicines Patent Pool announced Thursday The deal will see ViiV Healthcare a subsidiary of UK pharmaceutical giant GSK allow select manufacturers to produce generic versions of Cabotegravir LA its long acting pre exposure prophylaxis PrEP treatment for HIV The deal will provide access to the injectable version of cabotegravir which has been shown to provide two months of protection against infection in 90 countries where more than 70 percent of all new HIV infections occurred in 2020 Unitaid said Access to an effective long acting HIV prevention option could make a significant contribution to the goal of ending HIV transmission and the epidemic by 2030 Unitaid spokesman Herve Verhoosel said Efforts to increase access to Cabotegravir LA for PrEP will have a particular impact for groups experiencing particularly high rates of infection such as men who have sex with men and sex workers he added Long acting cabotegravir injections have only recently become available and have been shown to be much more effective than an oral version that must be taken daily But cost the price of a year s worth of treatment was 22 000 in the United States earlier this year was an obstacle to widespread implementation in all but high income countries Top global priority The World Health Organization released new guidelines on cabotegravir on Thursday calling on countries to work to make the drug quickly available to those who need it We hope that these new guidelines will help accelerate countries efforts to begin planning for and offering CAB LA alongside other HIV prevention options said Meg Doherty director of global HIV hepatitis and sexually transmitted infections programs of the WHO in a statement The news comes a day after a new report presented at the International AIDS Conference in Montreal Canada which found that the global fight against HIV has stalled due to reduced resources due to Covid 19 and other crises Last year there were around 1 5 million new infections more than a million above global goals to fight the virus Long acting PrEP could play an important role in ending the HIV pandemic but right now very few people can get it said Adeeba Kamarulzaman president of the International AIDS Society which is organizing the conference Expanding affordable access to this game changing prevention tool must be a global priority he said in a statement Unitaid is a global health initiative that works to ensure equitable access to medical innovations in low and middle income countries The Medicines Patent Fund founded by Unitaid and supported by the UN works to obtain licenses for medicines needed for generic distribution in low and middle income countries
    They reach an agreement for a generic drug to prevent HIV infection
    Foreign2 months ago

    They reach an agreement for a generic drug to prevent HIV infection

    An agreement has been reached to allow the distribution of a low-cost generic version of a long-term preventive HIV treatment in low-income countries where most of the world's infections occur, Unitaid and the Medicines Patent Pool announced Thursday. .

    The deal will see ViiV Healthcare, a subsidiary of UK pharmaceutical giant GSK, allow select manufacturers to produce generic versions of Cabotegravir LA, its long-acting pre-exposure prophylaxis (PrEP) treatment for HIV.

    The deal will provide access to the injectable version of cabotegravir, which has been shown to provide two months of protection against infection, in 90 countries where more than 70 percent of all new HIV infections occurred in 2020, Unitaid said.

    “Access to an effective long-acting HIV prevention option could make a significant contribution to the goal of ending HIV transmission and the epidemic by 2030,” Unitaid spokesman Herve Verhoosel said.

    "Efforts to increase access to Cabotegravir LA for PrEP will have a particular impact for groups experiencing particularly high rates of infection, such as men who have sex with men and sex workers," he added.

    Long-acting cabotegravir injections have only recently become available and have been shown to be much more effective than an oral version that must be taken daily.

    But cost — the price of a year's worth of treatment was $22,000 in the United States earlier this year — was an obstacle to widespread implementation in all but high-income countries.

    'Top global priority' The World Health Organization released new guidelines on cabotegravir on Thursday, calling on countries to work to make the drug quickly available to those who need it.

    "We hope that these new guidelines will help accelerate countries' efforts to begin planning for and offering CAB-LA alongside other HIV prevention options," said Meg Doherty, director of global HIV, hepatitis and sexually transmitted infections programs. of the WHO, in a statement.

    The news comes a day after a new report presented at the International AIDS Conference in Montreal, Canada, which found that the global fight against HIV has stalled due to reduced resources due to Covid-19 and other crises. .

    Last year there were around 1.5 million new infections, more than a million above global goals to fight the virus.

    “Long-acting PrEP could play an important role in ending the HIV pandemic, but right now very few people can get it,” said Adeeba Kamarulzaman, president of the International AIDS Society, which is organizing the conference.

    "Expanding affordable access to this game-changing prevention tool must be a global priority," he said in a statement.

    Unitaid is a global health initiative that works to ensure equitable access to medical innovations in low- and middle-income countries.

    The Medicines Patent Fund, founded by Unitaid and supported by the UN, works to obtain licenses for medicines needed for generic distribution in low- and middle-income countries.

  •   WHO today released new guidelines for the use of long acting injectable cabotegravir CAB LA as pre exposure prophylaxis PrEP for HIV calling on countries to consider this safe and highly effective prevention option for people at considerable risk of HIV infection The guidelines released ahead of the 24th International AIDS Conference AIDS 2022 will help countries plan for the introduction of CAB LA as part of a comprehensive approach to HIV prevention and will facilitate operational research urgently needed The guidelines are released at a critical time as HIV prevention efforts have stalled with 1 5 million new HIV infections in 2021 the same as in 2020 There were 4 000 new infections every day in 2021 with key populations sex workers men who have sex with men people who inject drugs people in prison and transgender people and their sexual partners who account for 70 of HIV infections worldwide Long acting cabotegravir is a safe and highly effective HIV prevention tool but it is not yet available outside study settings said Dr Meg Doherty director of the Global HIV Hepatitis and Infections Programs at WHO Sexual Transmission We hope that these new guidelines will help accelerate countries efforts to begin planning for and offering CAB LA alongside other HIV prevention options including oral PrEP and the dapivirine vaginal ring CAB LA is a long acting intramuscular injectable form of PrEP with the first 2 injections given 4 weeks apart followed by one injection every 8 weeks CAB LA was shown to be safe and highly effective among cisgender women cisgender men who have sex with men and transgender women who have sex with men in 2 randomized controlled trials HPTN 083 and HPTN 084 Together these landmark studies found that the use of CAB LA resulted in a 79 relative reduction in HIV risk compared to oral PrEP where adherence to daily oral medication intake was often challenging Long acting injectable products have also been found to be acceptable and sometimes preferred in studies examining community PrEP preferences Today s press conference also marks the launch of a new coalition to accelerate global access to CAB LA Convened by WHO Unitaid UNAIDS and the Global Fund the coalition will identify the market interventions needed to promote access to CAB LA in the short and long term establish financing and procurement of the medicine provide support for the implementation of global HIV prevention programs and issuing policy guidance among other activities To achieve the UN prevention goals we must drive rapid and equitable access to all effective prevention tools including long acting PrEP said Rachel Baggaley Programs Testing Prevention and Populations team lead Global HIV Hepatitis and STI in WHO That means overcoming critical barriers in low and middle income countries including implementation challenges and costs WHO will continue to support evidence based strategies to increase access to and uptake of PrEP including through the adoption of CAB LA Key actions include WHO will support countries and partners to safely and effectively include CAB LA in HIV prevention programmes WHO is working with Unitaid and other partners to develop implementation science projects to respond to outstanding safety issues implementation challenges and understand people s preferences for CAB LA among other HIV prevention options WHO is working with countries communities and donors including the Global Fund PEPFAR and the Bill amp Melinda Gates Foundation to support the inclusion of CAB LA in their programs and to catalyze implementation science and program monitoring to that CAB LA can be implemented safely and effectively to achieve the greatest impact The WHO Global PrEP Network will host webinars this year on CAB LA to provide up to date information to countries communities and implementers and raise awareness In April 2022 CAB LA was added to the WHO Expressions of Interest list for prequalification evaluation and WHO is working with countries on regulatory approval Both oral PrEP and CAB LA are very effective WHO will continue to support prevention options CAB LA increases the options available and should always be offered alongside oral PrEP Some people may still choose oral PrEP and people who find it difficult to take tablets or who don t want to take them may prefer CAB LA WHO has also released new differentiated and simplified PrEP guidance at the AIDS 2022 conference to support easier access including community delivery Consistent with previous WHO guidelines the new CAB LA guidelines are based on a public health approach that considers efficacy acceptability feasibility and resource needs in a variety of settings The guidelines are designed to facilitate the delivery of urgently needed CAB LA and operational research to address implementation and security issues These will inform decisions on how to successfully deliver and expand CAB LA The guidelines highlight critical research gaps including issues related to HIV drug resistance HIV testing service delivery models resource requirements safety in pregnancy and lactation and provision of CAB LA in geographic regions and for populations not included in the trials The guidelines also note that youth and key populations often experience challenges accessing current PrEP services Communities must be involved in the development and delivery of HIV prevention services that are effective acceptable and supportive of choice
    WHO recommends long-acting cabotegravir for HIV prevention
      WHO today released new guidelines for the use of long acting injectable cabotegravir CAB LA as pre exposure prophylaxis PrEP for HIV calling on countries to consider this safe and highly effective prevention option for people at considerable risk of HIV infection The guidelines released ahead of the 24th International AIDS Conference AIDS 2022 will help countries plan for the introduction of CAB LA as part of a comprehensive approach to HIV prevention and will facilitate operational research urgently needed The guidelines are released at a critical time as HIV prevention efforts have stalled with 1 5 million new HIV infections in 2021 the same as in 2020 There were 4 000 new infections every day in 2021 with key populations sex workers men who have sex with men people who inject drugs people in prison and transgender people and their sexual partners who account for 70 of HIV infections worldwide Long acting cabotegravir is a safe and highly effective HIV prevention tool but it is not yet available outside study settings said Dr Meg Doherty director of the Global HIV Hepatitis and Infections Programs at WHO Sexual Transmission We hope that these new guidelines will help accelerate countries efforts to begin planning for and offering CAB LA alongside other HIV prevention options including oral PrEP and the dapivirine vaginal ring CAB LA is a long acting intramuscular injectable form of PrEP with the first 2 injections given 4 weeks apart followed by one injection every 8 weeks CAB LA was shown to be safe and highly effective among cisgender women cisgender men who have sex with men and transgender women who have sex with men in 2 randomized controlled trials HPTN 083 and HPTN 084 Together these landmark studies found that the use of CAB LA resulted in a 79 relative reduction in HIV risk compared to oral PrEP where adherence to daily oral medication intake was often challenging Long acting injectable products have also been found to be acceptable and sometimes preferred in studies examining community PrEP preferences Today s press conference also marks the launch of a new coalition to accelerate global access to CAB LA Convened by WHO Unitaid UNAIDS and the Global Fund the coalition will identify the market interventions needed to promote access to CAB LA in the short and long term establish financing and procurement of the medicine provide support for the implementation of global HIV prevention programs and issuing policy guidance among other activities To achieve the UN prevention goals we must drive rapid and equitable access to all effective prevention tools including long acting PrEP said Rachel Baggaley Programs Testing Prevention and Populations team lead Global HIV Hepatitis and STI in WHO That means overcoming critical barriers in low and middle income countries including implementation challenges and costs WHO will continue to support evidence based strategies to increase access to and uptake of PrEP including through the adoption of CAB LA Key actions include WHO will support countries and partners to safely and effectively include CAB LA in HIV prevention programmes WHO is working with Unitaid and other partners to develop implementation science projects to respond to outstanding safety issues implementation challenges and understand people s preferences for CAB LA among other HIV prevention options WHO is working with countries communities and donors including the Global Fund PEPFAR and the Bill amp Melinda Gates Foundation to support the inclusion of CAB LA in their programs and to catalyze implementation science and program monitoring to that CAB LA can be implemented safely and effectively to achieve the greatest impact The WHO Global PrEP Network will host webinars this year on CAB LA to provide up to date information to countries communities and implementers and raise awareness In April 2022 CAB LA was added to the WHO Expressions of Interest list for prequalification evaluation and WHO is working with countries on regulatory approval Both oral PrEP and CAB LA are very effective WHO will continue to support prevention options CAB LA increases the options available and should always be offered alongside oral PrEP Some people may still choose oral PrEP and people who find it difficult to take tablets or who don t want to take them may prefer CAB LA WHO has also released new differentiated and simplified PrEP guidance at the AIDS 2022 conference to support easier access including community delivery Consistent with previous WHO guidelines the new CAB LA guidelines are based on a public health approach that considers efficacy acceptability feasibility and resource needs in a variety of settings The guidelines are designed to facilitate the delivery of urgently needed CAB LA and operational research to address implementation and security issues These will inform decisions on how to successfully deliver and expand CAB LA The guidelines highlight critical research gaps including issues related to HIV drug resistance HIV testing service delivery models resource requirements safety in pregnancy and lactation and provision of CAB LA in geographic regions and for populations not included in the trials The guidelines also note that youth and key populations often experience challenges accessing current PrEP services Communities must be involved in the development and delivery of HIV prevention services that are effective acceptable and supportive of choice
    WHO recommends long-acting cabotegravir for HIV prevention
    Africa2 months ago

    WHO recommends long-acting cabotegravir for HIV prevention

    WHO today released new guidelines for the use of long-acting injectable cabotegravir (CAB-LA) as pre-exposure prophylaxis (PrEP) for HIV, calling on countries to consider this safe and highly effective prevention option for people at considerable risk of HIV infection.

    .

    The guidelines, released ahead of the 24th International AIDS Conference (AIDS 2022), will help countries plan for the introduction of CAB-LA as part of a comprehensive approach to HIV prevention and will facilitate operational research urgently needed.

    The guidelines are released at a critical time as HIV prevention efforts have stalled with 1.5 million new HIV infections in 2021, the same as in 2020.

    There were 4,000 new infections every day in 2021, with key populations (sex workers, men who have sex with men, people who inject drugs, people in prison and transgender people) and their sexual partners, who account for 70% of HIV infections worldwide.

    “Long-acting cabotegravir is a safe and highly effective HIV prevention tool, but it is not yet available outside study settings,” said Dr. Meg Doherty, director of the Global HIV, Hepatitis and Infections Programs at WHO Sexual Transmission.

    "We hope that these new guidelines will help accelerate countries' efforts to begin planning for and offering CAB-LA alongside other HIV prevention options, including oral PrEP and the dapivirine vaginal ring."

    CAB-LA is a long-acting intramuscular injectable form of PrEP, with the first 2 injections given 4 weeks apart, followed by one injection every 8 weeks.

    CAB-LA was shown to be safe and highly effective among cisgender women, cisgender men who have sex with men, and transgender women who have sex with men in 2 randomized controlled trials, HPTN 083 and HPTN 084.

    Together, these landmark studies found that the use of CAB-LA resulted in a 79% relative reduction in HIV risk compared to oral PrEP, where adherence to daily oral medication intake was often challenging.

    Long-acting injectable products have also been found to be acceptable and sometimes preferred in studies examining community PrEP preferences.

    Today's press conference also marks the launch of a new coalition to accelerate global access to CAB-LA.

    Convened by WHO, Unitaid, UNAIDS and the Global Fund, the coalition will identify the market interventions needed to promote access to CAB-LA in the short and long term, establish financing and procurement of the medicine, provide support for the implementation of global HIV prevention programs and issuing policy guidance, among other activities.

    “To achieve the UN prevention goals, we must drive rapid and equitable access to all effective prevention tools, including long-acting PrEP,” said Rachel Baggaley, Programs Testing, Prevention and Populations team lead.

    Global HIV, Hepatitis and STI in WHO.

    "That means overcoming critical barriers in low- and middle-income countries, including implementation challenges and costs."

    WHO will continue to support evidence-based strategies to increase access to and uptake of PrEP, including through the adoption of CAB-LA.

    Key actions include: WHO will support countries and partners to safely and effectively include CAB-LA in HIV prevention programmes.

    WHO is working with Unitaid and other partners to develop implementation science projects to respond to outstanding safety issues, implementation challenges, and understand people's preferences for CAB-LA, among other HIV prevention options.

    WHO is working with countries, communities, and donors, including the Global Fund, PEPFAR, and the Bill & Melinda Gates Foundation, to support the inclusion of CAB-LA in their programs and to catalyze implementation science and program monitoring to that CAB-LA can be implemented, safely and effectively, to achieve the greatest impact.

    The WHO Global PrEP Network will host webinars this year on CAB-LA to provide up-to-date information to countries, communities and implementers and raise awareness.

    In April 2022, CAB-LA was added to the WHO Expressions of Interest list for prequalification evaluation, and WHO is working with countries on regulatory approval.

    Both oral PrEP and CAB-LA are very effective.

    WHO will continue to support prevention options.

    CAB-LA increases the options available and should always be offered alongside oral PrEP.

    Some people may still choose oral PrEP, and people who find it difficult to take tablets or who don't want to take them may prefer CAB-LA.

    WHO has also released new differentiated and simplified PrEP guidance at the AIDS 2022 conference to support easier access, including community delivery.

    Consistent with previous WHO guidelines, the new CAB-LA guidelines are based on a public health approach that considers efficacy, acceptability, feasibility, and resource needs in a variety of settings.

    The guidelines are designed to facilitate the delivery of urgently needed CAB-LA and operational research to address implementation and security issues.

    These will inform decisions on how to successfully deliver and expand CAB-LA.

    The guidelines highlight critical research gaps, including issues related to HIV drug resistance, HIV testing, service delivery models, resource requirements, safety in pregnancy and lactation, and provision of CAB-LA in geographic regions and for populations not included in the trials.

    The guidelines also note that youth and key populations often experience challenges accessing current PrEP services.

    Communities must be involved in the development and delivery of HIV prevention services that are effective, acceptable and supportive of choice.